4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vaxcyte, Inc. (PCVX) operates in the Biotechnology industry and is headquartered in San Carlos, United States with about 507 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, PCVX reported $0M in revenue and ($767M) in net income.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($924M) | ($570M) | ($393M) | ($209M) | — |
| Net Income | ($767M) | ($464M) | ($402M) | ($224M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($346M) | ($274M) | ($242M) | ($226M) | ($181M) | — |
| Net Income | ($321M) | ($246M) | ($213M) | ($167M) | ($141M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $3.0B | $3.5B | $1.4B | $1.0B | — |
| Total Liabilities | $317M | $206M | $167M | $53M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PCVX viewer.
About TickerBase · Data methodology & sources